All In Biotech

Drug Trial Radar · NCT07448155

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

A Phase 1, Single Dose, Open-Label, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

108

Actual

Start

Mar 19, 2026

Primary completion

Nov 14, 2026

Study completion Nov 14, 2026

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the pharmacokinetics, safety, and tolerability of INCA033989 following subcutaneous (SC) or intravenous administration (IV) n healthy adult participants.

Conditions

  • Healthy Participants

Interventions

  • INCA033989Drug

    INCA033989 will be administered at protocol defined dose.

  • Bioavailability enhancerDrug

    A bioavailability enhancer will be administered with INCA033989 at protocol defined dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics Parameter: Cmax of INCA33989 following a single SC administration compared with a single IV infusionTime frame: Up to 12 weeks
  2. Pharmacokinetics Parameter: AUClast of INCA33989 following a single SC administration compared with a single IV infusionTime frame: Up to 12 weeks
  3. Pharmacokinetics Parameter: AUC0∞ of INCA33989 following a single SC administration compared with a single IV infusionTime frame: Up to 12 weeks
  4. Number of participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion Clinical Research Unit

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.